Cyclophosphamide

Titlesort descending Average Rating
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patient 80.00%
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and 50.00%
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe 50.00%
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic bre 70.00%
Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma 70.00%
Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. 80.00%
SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel 60.00%
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer 70.00%
A case of metronomic chemotherapy as an alternative cancer therapy for palliation 60.00%
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin.... 50.00%
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses 70.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer.
Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. 70.00%
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. 50.00%
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy 50.00%
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refract 80.00%
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. 90.00%
Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's .... 90.00%
Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. 80.00%
Different metronomic treatment schedules 80.00%
Dose-Dense and/or Metronomic Schedules of Specific Chemotherapies Consolidate the Chemosensitivity of Triple-Negative Breast Can 63.33%
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide r 70.00%
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regi 80.00%
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and re 70.00%
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer with metronomic UFT + CP 60.00%
Hyperthermia adds to chemotherapy. 90.00%
Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. 80.00%
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosp 50.00%
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. 60.00%
Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer..... 75.00%
Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo. 40.00%
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. 90.00%
Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. 40.00%
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. 60.00%
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. 70.00%
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. 80.00%
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor acti 90.00%
Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. 70.00%
Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomiz 25.00%
Oral metronomic cyclophosphamide in elderly with metastatic melanoma. 70.00%
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. 30.00%
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) ...... 95.00%
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination wit 70.00%
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. 70.00%
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. 50.00%
The anti-angiogenic basis of metronomic chemotherapy. 85.00%
The PEP-C regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. 90.00%
Tumor pO(2) as a Surrogate Marker to Identify Therapeutic Window during Metronomic Chemotherapy of 9L Gliomas. 60.00%
Tumoral angiogenesis: review of the literature. 50.00%